ARS Pharmaceuticals, Inc. (SPRY) scores 47 out of 100 on boothcheck's 11-model valuation framework. Verdict: Poor The estimated fair value is 0.85, representing a 90% premium to fair value. Quantitative score: 39/100. Qualitative score: 90/100.
Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.